Is RXRX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on An industrial-scale AI platform and proprietary data moat, with revenue (q1 2026) at ~$6.5 million (mostly partnership and milestone revenue, missed analyst estimates). The bear case rests on the central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output. Analysts covering it are spread from $4.00 to $10.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $4.00, +33.3% from the $3.00 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

An industrial-scale AI platform and proprietary data moat. Recursion's core argument is that drug discovery becomes a data and compute problem at scale. The most optimistic analyst target on RXRX is $10.00, +233.3% from the $3.00 price. That figure is only reachable if this thesis works close to its best case.

The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output. AI-driven drug discovery as a category is still unproven at the finish line, and skeptics note that no AI-originated compound has yet delivered a blockbuster approval, leaving open the possibility that the platform advantage does not translate into clinical success. Recursion's Phase 2 candidates could fail in trials like most clinical-stage biotech assets do, and even partnered programs depend on decisions outside Recursion's control. Although the company guides to a cash runway into early 2028, continued losses mean it may need to raise capital again, and equity raises would dilute existing shareholders; the stock has also been volatile, trading well below prior highs. The most pessimistic published target is $4.00, +33.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Recursion Pharmaceuticals is a Salt Lake City-based, clinical-stage technology-enabled biopharmaceutical company that aims to industrialize drug discovery.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (An industrial-scale AI platform and proprietary data moat) stalling in the reported numbers rather than in the narrative, the risk above (the central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends entirely on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a scaled AI platform, deep pharma partnerships, and a cash runway into early 2028. The bear case is that Recursion has no approved drug, loses over $100 million a quarter, and could fail in trials or need dilutive financing. It is a speculative, high-volatility holding, not a stable one.

Recursion is a clinical-stage biotech that aims to industrialize drug discovery using artificial intelligence. It runs automated biology experiments at massive scale, captures the results as proprietary imaging data, and uses machine-learning models, plus Exscientia's molecular design tools, to identify and design drug candidates. It earns money mainly through partnerships with large pharma companies and is advancing its own pipeline of experimental medicines.

No. Recursion is not profitable and remains deeply loss-making, reporting a net loss of roughly $117.5 million in the first quarter of 2026 against only about $6.5 million of revenue. Like most clinical-stage biotech companies, it spends heavily on research and trials years before any product could generate meaningful sales, so profitability is not expected in the near term.